Algernon Pharmaceuticals Inc.
AGNPF
$0.063
$0.00916.67%
| Weiss Ratings | AGNPF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Very Weak | |||
| Risk Index | Weak | |||
| Risk Grade | D- | |||
| Reward Grade | E | |||
| Rating Factors | AGNPF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | -- | |||
| Growth Index | Fair | |||
| Efficiency Index | Very Weak | |||
| Solvency Index | Fair | |||
| Total Return Index | Weak | |||
| Volatility Index | Weak | |||
| Beta / Standard Deviation | AGNPF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | -0.40 | |||
| Price History | AGNPF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | -2.33% | |||
| 30-Day Total Return | 0.32% | |||
| 60-Day Total Return | 26.00% | |||
| 90-Day Total Return | 14.55% | |||
| Year to Date Total Return | 36.07% | |||
| 1-Year Total Return | 3.62% | |||
| 2-Year Total Return | -68.50% | |||
| 3-Year Total Return | -113.08% | |||
| 5-Year Total Return | -118.52% | |||
| 52-Week High % Change | -56.10% | |||
| 52-Week Low % Change | 44.00% | |||
| Price | AGNPF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $0.12 | |||
| 52-Week Low Price | $0.04 | |||
| 52-Week Low Price (Date) | Dec 20, 2024 | |||
| 52-Week High Price (Date) | May 22, 2024 | |||
| Valuation | AGNPF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | 1.54M | |||
| Enterprise Value | 1.29M | |||
| Price/Earnings (TTM) | -- | |||
| Earnings Per Share (TTM) | -0.02 | |||
| Earnings Per Share Growth | -92.95% | |||
| Price/Earnings To Growth | -- | |||
| Price/Sales (TTM) | -- | |||
| Price/Book (Q) | 1.16 | |||
| Enterprise Value/Revenue (TTM) | -- | |||
| Price | $0.06 | |||
| Enterprise Value/EBITDA (TTM) | -0.82 | |||
| Enterprise Value/EBIT | -0.81 | |||
| Market Cap Category | Nano Cap | |||
| Dividends and Shares | AGNPF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 27.30M | |||
| Dividend Yield | -- | |||
| Div. Per Share (Most Recent) | -- | |||
| Dividend Per Share (TTM) | -- | |||
| Payout Ratio (TTM) | -- | |||
| Dividend Per Share (Most Recent) | -- | |||
| Company Info | AGNPF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | 604 398 4175 | |||
| Address | 601 West Broadway Vancouver, BC V5Z 4C2 | |||
| Website | algernonpharmaceuticals.com | |||
| Country | Canada | |||
| Year Founded | 2015 | |||
| Profitability | AGNPF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | -- | |||
| Profit Margin | -- | |||
| Management Effectiveness | AGNPF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | -35.96% | |||
| Return on Equity | -- | |||
| Income Statement | AGNPF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | -- | |||
| Total Revenue (TTM) | -- | |||
| Revenue Per Share | -- | |||
| Gross Profit (TTM) | -- | |||
| EBITDA (TTM) | -1.57M | |||
| EBIT (TTM) | -1.59M | |||
| Net Income (TTM) | -272.30K | |||
| Net Income Avl. to Common (TTM) | -272.30K | |||
| Total Revenue Growth (Q YOY) | -- | |||
| Earnings Growth (Q YOY) | 27.49% | |||
| EPS Diluted (TTM) | -0.02 | |||
| EPS Diluted Growth (Q YOY) | 58.26% | |||
| Balance Sheet | AGNPF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | 255.50K | |||
| Cash Per Share (Q) | $0.01 | |||
| Total Current Assets (Q) | 303.90K | |||
| Total Preferred Equity (Q) | -- | |||
| Total Equity (Q) | 1.28M | |||
| Current Ratio (Q) | 0.228 | |||
| Book Value Per Share (Q) | $0.05 | |||
| Total Assets (Q) | 2.61M | |||
| Total Current Liabilities (Q) | 1.33M | |||
| Total Debt (Q) | 0.00 | |||
| Total Liabilities (Q) | 1.33M | |||
| Total Common Equity (Q) | 1.28M | |||
| Cash Flow | AGNPF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | 1.67M | |||
| Cash from Financing (TTM) | 662.00K | |||
| Net Change in Cash (TTM) | 210.00K | |||
| Levered Free Cash Flow (TTM) | -1.67M | |||
| Cash from Operations (TTM) | -2.13M | |||
